Citadel Advisors’s Vivos Therapeutics VVOS Stock Holding History
Bought
Maintained
Sold
Other funds holding VVOS
Citadel Advisors's VVOS Position: Q3 2026 in Review
Citadel Advisors opened a new position in Vivos Therapeutics (VVOS) in Q3 2026: 491,378 shares worth $72.7K. The stake represents ﹤0.01% of the portfolio and ranks #13142 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in VVOS as recently as Q4 2022.
Citadel Advisors first reported a position in VVOS in Q1 2021 and has held it in 6 quarters since. The position peaked at $320K in Q3 2021. 27 funds tracked by Wall St. Rank hold VVOS as of Q3 2026.
- Citadel Advisors held 491,378 shares of Vivos Therapeutics worth $72.7K as of Q3 2026.
- Vivos Therapeutics was a new Citadel Advisors position in Q3 2026.
- Vivos Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #13142 holding.
- Citadel Advisors first reported a position in Vivos Therapeutics in Q1 2021 and has held it in 6 quarters since.
- Citadel Advisors's Vivos Therapeutics position peaked at $320K in Q3 2021.
- 27 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.